CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases. The review, encompassing 19 studies, reveals a high incidence of CRS in patients with ...
While the use of chimeric antigen receptor (CAR) T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to ...
Like traditional biologics, cell and gene therapies (CGTs) must meet safety and efficacy standards before they can be administered to human patients. But the manufacturing processes used for this new ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Universal, off‑the‑shelf CAR‑T cell therapies using gene‑edited donor T cells are beginning ...
Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results